Related Experiment Video
Updated: Apr 19, 2026
An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas
Published on: October 10, 2025
Neurofibromatosis-related tumors: emerging biology and therapies
Matthias A Karajannis1, Rosalie E Ferner
1aDepartments of Pediatrics and Otolaryngology, Division of Pediatric Hematology/Oncology, NYU Langone Medical Center, New York, USA bDepartment of Neurology, Guy's and St Thomas' NHS Foundation Trust, and Department of Clinical Neuroscience, Institute of Psychiatry, King's College London, London, UK.
Purpose Of Review:
Over the past decade, substantial insight into the biological function of the tumor suppressors neurofibromin (NF1) and Merlin (NF2) has been gained. The purpose of this review is to highlight some of the major advances in our understanding of the biology of neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2) as they relate to the development of novel therapies for these disorders.
Recent Findings:
The development of increasingly sophisticated preclinical models over the recent years has provided the platform from which to rationally develop molecular targeted therapies for both NF1 and NF2-related tumors, such as within the Department of Defense-sponsored Neurofibromatosis Clinical Trials Consortium.
Summary:
Clinical trials with molecular-targeted therapies have become a reality for neurofibromatosis patients, and hold substantial promise for improving the morbidity and mortality of individuals affected with these disorders.
Insights
Advances in understanding neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2) biology are driving novel molecularly targeted therapies. Clinical trials show promise for improving outcomes in NF1 and NF2 patients.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2) are genetic disorders characterized by tumor suppressor gene dysfunction.
- Significant progress has been made in understanding the biological roles of NF1 and NF2 proteins.
Purpose of the Study:
- To review major advancements in NF1 and NF2 biology.
- To highlight the development of novel therapies for NF1 and NF2-related disorders.
Main Methods:
- Review of recent scientific literature and clinical trial data.
- Analysis of preclinical models for NF1 and NF2.
Main Results:
- Sophisticated preclinical models have enabled the rational development of molecularly targeted therapies.
- The Department of Defense-sponsored Neurofibromatosis Clinical Trials Consortium is advancing therapeutic strategies.
Conclusions:
- Molecular-targeted therapies are now being tested in clinical trials for neurofibromatosis patients.
- These novel therapies hold significant potential to reduce morbidity and mortality associated with NF1 and NF2.
More Related Videos
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
